Metabasis Therapeutics, Inc.

Sankyo Company, Limited

Sumitomo Pharmaceuticals Company Limited

Gerard Robert Scarlato

Mark D Erion

Qun Dang

K Raja Reddy

Srinivas Rao Kasibhatla

M Rami Reddy

Yumiko Kamikawa

Masashi Nakatsuka

Fumio Samizo

Tamiki Nishimura

Hitoshi Houtigai

Sara Sabina Hadida Ruah

A hydroxamic acid derivative represented by formula (1) or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which has a matrix metalo-proteinase inhibitor.

Hydroxamic acid derivatives

Novel benzimidazole compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described

Benzimidazole inhibitors of fructose 1,6-bisphosphatase

The present invention is directed towards novel azaindole compounds which bind to the AMP site and are potent FBPase inhibitors. The present invention also is directed towards the clinical use of the novel FBPase inhibitors as a method of treatment or prevention of diseases responsive to lowered blood glucose levels.

Indole and azaindole inhibitors of Fructose-1,6-biphosphatase

Novel benzimidazole compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described ##STR1##

Novel indole and azaindole compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described: ##STR1## and pharmaceutically acceptable prodrugs and salts thereof.

Growing community of inventors

La Jolla, CA, United States of America

Gerard Robert Scarlato